ARTICLE COMPARING SURVIVAL OUTCOMES OF ISOLATED LIMB INFUSION VERSUS PV-10 FOR IN-TRANSIT MELANOMA PUBLISHED IN JOURNAL OF SURGICAL ONCOLOGY - 72 patients were treated with either ILI or PV-10 at Australia’s Princess Alexandra Hospital; data were prospectively recorded; primary outcome was melanoma-specific survival; ILI is historical...

PROVECTUS BIOPHARMACEUTICALS ANNOUNCES CHANGES TO BOARD OF DIRECTORS FOR IMMEDIATE RELEASE Ed Pershing, CPA elected new Board chair Jack Lacey, MD named new Board director; also appointed new strategic advisory board chair KNOXVILLE, TN, April 24, 2018 ...

SECOND STUDY OF EXPANDED ACCESS PATIENTS TREATED WITH PV-10 FOR IN-TRANSIT MELANOMA PUBLISHED IN JOURNAL OF SURGICAL ONCOLOGY FOR IMMEDIATE RELEASE KNOXVILLE, TN, April 19, 2018 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com) (“Provectus” or the “Company”), a...